Title: Economic assessment
Subjects: Cost effectiveness, Chemotherapy, Therapeutic use, Rheumatoid arthritis, Nonsteroidal anti-inflammatory agents, Inhibitors, Rofecoxib, Osteoarthritis, Celecoxib, Cyclooxygenase 2